

**ADJUVANT SYSTEMIC THERAPY AND ADJUVANT RADIATION FOR STAGE I TO IIIA COMPLETELY RESECTED NON-SMALL-CELL-LUNG CANCERS: AMERICAN SOCIETY OF CLINICAL ONCOLOGY/CANCER CARE ONTARIO CLINICAL PRACTICE GUIDELINE UPDATE**

Clinical Question	Recommendation	Evidence Rating
What is the overall survival (OS) benefit of adjuvant systemic therapy in patients with completely resected stage I to IIIA NSCLCs?	Stage IA: Adjuvant chemotherapy is not recommended.	Type: Evidence based and Panel consensus Harms outweigh benefits Evidence quality: Intermediate <sup>1</sup> Strength of recommendation: Strong
	Stage IB: Adjuvant cisplatin-based chemotherapy is not recommended for routine use. A postoperative multimodality evaluation, including a consultation with a medical oncologist, is recommended to assess benefits and risks for adjuvant chemotherapy for each patient.	Type: Evidence based and Panel Consensus Benefits outweigh harms, especially in patients with larger tumors Evidence quality: Intermediate <sup>1</sup> Strength of recommendation: Moderate
	Stages IIA/B and IIIA: Adjuvant cisplatin-based chemotherapy is recommended.	Type: Evidence based and Panel consensus Benefits outweigh harms Evidence quality: High <sup>1</sup> Strength of recommendation: Strong
What is the OS benefit of adjuvant radiation therapy in patients with completely resected stage I to IIIA NSCLCs?	Stage IA/B and IIA/B: Adjuvant radiation therapy is not recommended.	Type: Evidence based and Panel consensus Harms outweigh benefits Evidence quality: Intermediate Strength of recommendation: Strong <sup>2</sup>
	Stage IIIA: Adjuvant radiation therapy is not recommended for routine use. A postoperative multimodality evaluation, including a consultation with a radiation oncologist, is recommended to assess benefits and risks of adjuvant radiotherapy in patients with N2 disease.	Type: Evidence based and Panel consensus Benefits outweigh harms Evidence quality: Intermediate <sup>3</sup> Strength of recommendation: Moderate

## References

1. Bradbury P, Sivajohanathan D, Chan A, et al: Postoperative adjuvant systemic therapy in completely resected non–small-cell lung cancer. Clin Lung Cancer [epub ahead of print on July 12, 2016]
2. Pisters KM, Evans WK, Azzoli CG, et al: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIa resectable non small-cell lung cancer guideline. J Clin Oncol 25:5506-5518, 2007
3. Rodrigues G, Choy H, Bradley J, et al: Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 5:149-155, 2015